Results 71 to 80 of about 14,793 (172)

Integrated HIV and TB Services for the Management of Coinfection in West Africa: A Scoping Review of Strategies, Outcomes, Barriers and Enablers

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aim There is a concern about treatment outcomes for human immunodeficiency virus and tuberculosis infections in West Africa. This has led to a focus on the development of strategies for integrated care; however, data on the barriers and enablers of these strategies are limited.
Chris Mensah Nartey, Adwoa Kumiwa Asare Afrane, Benjamin Tagoe, Awo Afi Kwapong, Seth Kwabena Amponsah   +4 more
wiley   +1 more source

In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors

Advances in Virology, 2012
Most antiretroviral medical treatments were developed and tested principally on HIV-1 B nonrecombinant strain, which represents less than 10% of the worldwide HIV-1-infected population.
Xiaoju Ni, Safwat Abdel-Azeim, Elodie Laine, Rohit Arora, Osamuede Osemwota, Anne-Geneviève Marcelin, Vincent Calvez, Jean-François Mouscadet, Luba Tchertanov   +8 more
doaj   +1 more source

Allosteric HIV Integrase Inhibitors Promote Formation of Inactive Branched Polymers via Homomeric Carboxy-Terminal Domain Interactions. [PDF]

Structure, 2021
Gupta K, Allen A, Giraldo C, Eilers G, Sharp R, Hwang Y, Murali H, Cruz K, Janmey P, Bushman F, Van Duyne GD.   +10 more
europepmc   +1 more source

SARS‐CoV‐2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV

Journal of Medical Virology, Volume 98, Issue 8, August 2026.
ABSTRACT This study examined changes in anti‐Spike (anti‐S) antibodies (Abs) and type I interferon (IFN‐I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second ...
Federica Frasca, Luca Maddaloni, Alessandra D'Auria, Matteo Fracella, Ginevra Bugani, Carmen Falvino, Valentina Baccolini, Giuseppe Migliara, Francesca Aloisi, Letizia Santinelli, Enrico Palermo, Luca Bortolani, Alessandro Lazzaro, Giancarlo Ceccarelli, Ombretta Turriziani, Claudio Maria Mastroianni, Guido Antonelli, Gabriella d'Ettorre, Carolina Scagnolari   +18 more
wiley   +1 more source

Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes. [PDF]

Cells, 2022
Ngono Ayissi K, Gorwood J, Le Pelletier L, Bourgeois C, Beaupère C, Auclair M, Foresti R, Motterlini R, Atlan M, Barrail-Tran A, Le Grand R, Desjardins D, Fève B, Lambotte O, Capeau J, Béréziat V, Lagathu C.   +16 more
europepmc   +1 more source

Recent Advances in the Molecular Mechanisms of Bacterial Anti‐Phage Defence Systems

Microbial Biotechnology, Volume 19, Issue 8, August 2026.
Panoptes as an example for an antiphage system consists of OptS producing a cyclic dinucleotide that prevents activation of OptE, a transmembrane protein. Phage T4 infection introduces the sponge protein Acb2 that adsorbs the cyclic dinucleotide thus activating OptE which disrupts the cell membrane aborting phage infection.
Harald Brüssow
wiley   +1 more source

HIV Integrase Inhibitors

, 2013
This chapter presents the discovery, development and evolution of integrase strand transfer inhibitors. A brief overview of the first‐generation inhibitors raltegravir and elvitegravir serves to describe their landmark advancement of the field and also outline areas for further improvement.
Brian A. Johns, Takashi Kawasuji, Emile J. Velthuisen   +2 more
openaire   +4 more sources

Potential benefit of dolutegravir once daily: efficacy and safety

HIV/AIDS: Research and Palliative Care, 2013
Alessandra Fantauzzi,1 Ombretta Turriziani,2 Ivano Mezzaroma11Department of Clinical Medicine, 2Department of Molecular Medicine, Sapienza, University of Rome, Rome, ItalyAbstract: The viral integrase enzyme has recently emerged as a primary alternative ...
Fantauzzi A, Turriziani O, Mezzaroma I
doaj  

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, Volume 27, Issue 8, Page 1241-1252, August 2026.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source

Brief Histories of Retroviral Integration Research and Associated International Conferences

Viruses
The field of retroviral integration research has a long history that started with the provirus hypothesis and subsequent discoveries of the retroviral reverse transcriptase and integrase enzymes.
Duane P. Grandgenett, Alan N. Engelman
doaj   +1 more source